Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 2CNS 2NET 1Endocrine 1Dermatologic 1

Conditions

Glioma 1Glioblastoma 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × TH 302 × CNS × Clear all
NCT02342379 2020-04-10

TH-302 in Combination With Bevacizumab for Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
35 enrolled 6 charts
CNS

Glioblastoma

NCT01403610 2019-07-24

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 9 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡